Spinraza
nusinersen · Biogen Netherlands B.V.
ORPHAN AUTHORISED IN THE EUWhat Spinraza is used for
Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Spinraza
- Active substance
- nusinersen
- Disease area
- Muscular Atrophy, Spinal
- Medicine group
- Other nervous system drugs
- ATC code
- M09
- Marketing authorisation holder
- Biogen Netherlands B.V.
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Spinraza used for?
Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.
What is the active substance in Spinraza?
Spinraza contains nusinersen.
Who makes Spinraza?
The EU marketing authorisation holder is Biogen Netherlands B.V..
Is Spinraza an orphan medicine?
Yes. Spinraza is designated an orphan medicine in the EU, for a rare disease (Muscular Atrophy, Spinal).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU